A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585
This study is recruiting at 8 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Squamous Non-small-cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Cervical Squamous Cell Carcinoma
- Esophageal Squamous Cell Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Alentis Therapeutics AG
- Last updated on ClinicalTrials.gov
- June 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Foundation for Medical Education and Research - Mayo Cl · Scottsdale, AZ
California · 2
- Providence Medical Foundation · Fullerton, CA
- USC Norris Comprehensive Cancer Center · Los Angeles, CA
Connecticut · 1
- Yale Comprehensive Cancer Center · New Haven, CT
Illinois · 1
- The University of Chicago Medical Center - Oncology · Chicago, IL
Kentucky · 1
- Norton Cancer Institue Downtown · Louisville, KY
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
Virginia · 1
- NEXT Oncology Virginia · Fairfax, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.